(Q37506661)

20 August 2017

1 reference

title

Treatment of urinary schistosomiasis: methodological issues and research needs identified through a Cochrane systematic review (English)

1 reference

20 August 2017

0 references

1 reference

urinary schistosomiasis

1 reference

2

1 reference

20 August 2017

A Danso-Appiah

1

1 reference

20 August 2017

P L Olliaro

series ordinal

3

1 reference

20 August 2017

J Utzinger

series ordinal

4

1 reference

20 August 2017

publication date

3 June 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

136

1 reference

20 August 2017

issue

13

1 reference

20 August 2017

page(s)

1837-1849

1 reference

Efficacy and side effects of praziquantel against Schistosoma mansoni in a community of western Côte d'Ivoire

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Reinfection with Schistosoma haematobium following school-based chemotherapy with praziquantel in four highly endemic villages in Côte d'Ivoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Praziquantel: a new schistosomicide against Schistosoma haematobium

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. An example of a complex study covering both tolerance and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Assessment of the age-specific disability weight of chronic schistosomiasis japonica

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Efficacy of a combination of praziquantel and artesunate in the treatment of urinary schistosomiasis in Nigeria

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Efficacy of artesunate in the treatment of urinary schistosomiasis, in an endemic community in Nigeria

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Metrifonate. Summary of toxicological and pharmacological information available

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Decision-model estimation of the age-specific disability weight for schistosomiasis japonica: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Drugs for the control of parasitic diseases: current status and development in schistosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Diagnostic techniques in schistosomiasis control. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Evidence for an immune-dependent action of praziquantel on Schistosoma mansoni in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Underestimation of Schistosoma mansoni prevalences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Efficacy of artesunate and praziquantel in Schistosoma haematobium infected schoolchildren

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Antischistosomal drugs: past, present ... and future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Bioavailability of praziquantel increases with concomitant administration of food

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Chemotherapy of schistosomiasis: present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Antischistosomal efficacy of artesunate combination therapies administered as curative treatments for malaria attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Artesunate and praziquantel for the treatment of Schistosoma haematobium infections: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

The influence of sampling effort and the performance of the Kato-Katz technique in diagnosing Schistosoma mansoni and hookworm co-infections in rural Côte d'Ivoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Trick or treat: the role of vaccines in integrated schistosomiasis control

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

The impact of population level deworming on the haemoglobin levels of schoolchildren in Tanga, Tanzania

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Field trial of the efficacy of a simplified and standard metrifonate treatments of Schistosoma haematobium

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Allocation concealment in randomised trials: defending against deciphering

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Sequential analysis of helminth egg output in human stool samples following albendazole and praziquantel administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Schistosoma mansoni: chemotherapy of infections of different ages

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Is Schistosomicidal Chemotherapy Sub-curative? Implications for Drug Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

Metrifonate for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

7 January 2021

Randomized comparison of low-dose versus standard-dose praziquantel therapy in treatment of urinary tract morbidity due to Schistosoma haema tobium infection.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

7 January 2021

Epidemiology of helminth infections: implications for parasite control programmes, a South African perspective.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

7 January 2021

Therapeutic properties of metrifonate.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

7 January 2021

Factors affecting infection or reinfection with Schistosoma haematobium in coastal Kenya: survival analysis during a nine-year, school-based treatment program.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

7 January 2021

Single dose oral treatment in urinary schistosomiasis: a double blind trial.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

7 January 2021

Proteinuria, hematuria, and leukocyturia in children with mixed urinary and intestinal schistosomiasis

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

7 January 2021

Praziquantel: is there real resistance and are there alternatives?

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

7 January 2021

Relationships of Schistosoma haematobium, hookworm and malarial infections and metrifonate treatment to growth of Kenyan school children

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

7 January 2021

Efficacy of praziquantel against Schistosoma haematobium infection in children.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

7 January 2021

Chemotherapy-based control of schistosomiasis haematobia. I. Metrifonate versus praziquantel in control of intensity and prevalence of infection.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

7 January 2021

Prophylaxis of schistosomiasis - field trial of metrifonate for the prevention of human infection

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

7 January 2021

Drugs for treating urinary schistosomiasis

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

7 January 2021

Single dose metrifonate or praziquantel treatment in Kenyan children. I. Effects on Schistosoma haematobium, hookworm, hemoglobin levels, splenomegaly, and hepatomegaly

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009005939

7 January 2021

10.1017/S0031182009005939

Identifiers

DOI

1 reference

20 August 2017

1 reference